Business Wire

ABS and SpaceX Sign JDP on Remotely Controlled Rocket Recovery Droneships

Share

ABS has signed a joint development project (JDP) with SpaceX to review the remotely controlled functions of autonomous rocket recovery droneships used for booster rocket recovery at sea.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005017/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

A SpaceX rocket recovery droneship, which will have its autonomous functions evaluated by ABS. Image courtesy of SpaceX

The rocket recovery droneships are modified to include an expanded deck to increase the size of the landing platform, four thruster engines for propulsion and to hold on station, and blast shielding to protect electrical and engine equipment on deck. The droneships are entirely unmanned during landings, with a robot deployed on board to secure the rocket booster to the droneship before the vessel returns to port.

The project will review the design of one of SpaceX’s three rocket recovery droneships for compliance with the ABS Guide for Autonomous and Remote-Control Functions. Due to the unique and challenging operating requirements, ABS will apply a risk-based approach to the evaluation of the autonomous functions.

“Through our work on autonomous and remote-control technologies in projects with leading partners all over the world, ABS has been leading the way in supporting its practical application at sea. This makes us ideally placed to work with SpaceX on its unique and exciting project. We are proud that our capabilities in this area have been recognized by a true pioneer such as SpaceX,” said Patrick Ryan, ABS Senior Vice President, Global Engineering and Technology.

ABS is a world leader in supporting the development of autonomous and remote-control functions at sea. A remotely operated harbor tug developed by Keppel Offshore & Marine was the first in the world to receive the ABS REMOTE-CON Notation in October 2021.

A copy of the ABS Guide for Autonomous and Remote-Control Functions can be downloaded here.

About ABS
ABS, a leading global provider of classification and technical advisory services to the marine and offshore industries, is committed to setting standards for safety and excellence in design and construction. Focused on safe and practical application of advanced technologies and digital solutions, ABS works with industry and clients to develop accurate and cost-effective compliance, optimized performance and operational efficiency for marine and offshore assets.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information, contact ABS Media Relations: glewis@eagle.org

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology27.6.2022 07:00:00 CEST | Press release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220626005092/en/ Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme. The transaction was unanimously approved by both Ipsen and Epizyme Boards of Directors and is anticipated to close by the end of the third quarter of 2022, subject to the satisfaction of all closing conditions. Epizyme is a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets for cancer patients. The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor, which was granted Accelerated Approval by the U.S. Food and Drug Administratio

The Group Announces the Beginning of An Open-Ended Share Repurchase Programme Of Prosus And Naspers Shares27.6.2022 06:00:00 CEST | Press release

The board of directors of Naspers Limited ("Naspers Board") (JSE: NPN; LSE: NPSN) and board of directors ("Prosus Board") of Prosus N.V. ("Prosus") (Euronext Amsterdam: PRX; JSE: PRX) are pleased to announce the beginning of an open-ended, repurchase programme in respect of the ordinary shares N in the capital of Prosus ("Prosus Shares") and N ordinary shares ("Naspers Shares") in the share capital of Naspers, from the respective Prosus and Naspers (together the "Group") free-float shareholders (together the "Repurchase Programme"). The Repurchase Programme is expected to efficiently unlock immediate value for the shareholders of Prosus ("Prosus Shareholders") and Naspers ("Naspers Shareholders"). Prosus will begin selling small numbers of ordinary shares in Tencent Holdings Limited (“Tencent”) held by the Group (“Tencent Shares”) regularly and in an orderly manner, while concurrently purchasing Prosus Shares and Naspers Shares pursuant to the Repurchase Programme, as long as the Group

The Group Announces the Beginning of an Open-Ended Share Repurchase Programme of Prosus and Naspers Shares27.6.2022 06:00:00 CEST | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, INTO OR IN ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. PLEASE SEE THE IMPORTANT NOTICE AND DISCLAIMERS AT THE END OF THIS ANNOUNCEMENT. The board of directors of Naspers Limited ("Naspers Board") (JSE: NPN; LSE: NPSN) and board of directors ("Prosus Board") of Prosus N.V. ("Prosus") (Euronext Amsterdam: PRX; JSE: PRX) are pleased to announce the beginning of an open-ended, repurchase programme in respect of the ordinary shares N in the capital of Prosus ("Prosus Shares") and N ordinary shares ("Naspers Shares") in the share capital of Naspers, from the respective Prosus and Naspers (together the "Group") free-float shareholders (together the "Repurchase Programme"). The Repurchase Programme is expected to efficiently unlock immediate value for the shareholders of Prosus ("Prosus Shareholders") and Naspers ("Naspers Shareholders"). Prosus will begin sellin

EPPA : New Study Shows That Making Reusable Containers for Takeaway Obligatory Will Undermine the EU’s Environmental Goals27.6.2022 06:00:00 CEST | Press release

Obligatory reusable packaging in takeaway services would be more burdensome for the environment than continuing to use single-use paper-based packaging. This is the conclusion of a new meta-study assessment, commissioned by the European Paper Packaging Alliance and carried out by renowned engineering consultancy, Ramboll. As the European Commission prepares to propose a revision of the Packaging and Packaging Waste Directive (PPWD) with potentially far-reaching implications, the analysis, which examined 26 scientific studies, shows that reuse systems impose exclusive additional burdens to the environment when compared to single-use, related to additional washing, take-back transportation and breakage / unit loss associated with takeaway. The results show that Climate Change is by far the most affected impact category when implementing reuse in take-away services, and that reusable tableware can also have a significant impact on water use. Commenting on the meta-study assessment, Eric L

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit